ASCO 2022 | ADI-001: anti-CD20 CAR-engineered allogeneic γδ T cells in adults with B-cell malignancies
Sattva Neelapu
• 5 Jun 2022
Sattva Neelapu, MD, MD Anderson Cancer Center, Houston, TX, discusses results from a Phase I study of ADI-001, a first-in-class allogeneic gamma delta (γδ) CAR T-cell therapy targeting the B-cell antigen CD20, in adult patients with B-cell malignancies. ADI-001 γδ CAR T cells were well tolerated, with a favorable safety profile and encouraging preliminary efficacy. Patients who achieved complete response at day 28 appeared to be disease free during further follow-up at 3 months. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
